Mankind is a long term play period. There are many reasons Sanofi is not going to push Afrezza hard just yet. But they will when the timing is right. Basically a multitiude of variables to work through and then ramp up will be fairly swift. I will just sit on my nice chunk of shares for a couple years and then maybe think about selling. By then the Technosphere part of the equation should be running hot.
The MD-360 Report: FDA Approval of Toujeo Means Afrezza Sales to Ramp Up Rapidly
Published: Monday, 02 March 2015 09:39 Written by Doctor Hung Tran, MD, MS
As what is seemingly a blessing to the MannKind shareholders and to hundred of million of patients worldwide, the United States FDA approved Toujeo on Friday Feb. 25, 2015.
With the aforementioned key event in placed by nearly five months early, Afrezza and Toujeo to witness a rapid up ramping of sales, much sooner than what the market anticipated was a “controlled launch.”
We have developed the Technosphere® Technology Platform, a versatile delivery system that mimics the pharmacokinetics of intra-arterial administration.
Technosphere technology allows the pulmonary administration of therapeutics currently requiring administration by injection and offers several competitive advantages over other pulmonary drug delivery systems.
The unique pharmacokinetic profiles of drugs inhaled as Technosphere formulations have the potential to provide significant competitive advantages over drugs delivered via other delivery systems, including:
Applicability to a wide variety of drugs
Rapid drug absorption that mimics intra-arterial delivery